Greater Hartford
I am an executive HR and people strategy leader operating at the intersection of financial services, professional services, and private equity while partnering with CEOs, Boards, and investors to scale organizations, strengthen leadership, and drive enterprise value. As Chief People Officer for a $10B+ AUM wealth management firm, I lead the HR function and enterprise people strategy during a period of rapid geographic expansion and organizational growth. My career spans multiple CHRO/CPO/Head of HR roles and senior leadership experience across Fortune 100 institutions, PE-backed platforms, and high-growth companies - with a consistent focus on helping organizations navigate scale, M&A, and transformation. Over the course of my career, I’ve partnered with leadership teams to: • Scale organizations from 30 to 2,000 employees and $5M to $300M in revenue • Support $1B+ private equity exits and global M&A integrations • Build global workforces of 18,000+ employees across 800+ operating sites • Deliver multi-million-dollar cost transformations and restructuring initiatives • Stand up enterprise governance, analytics, and operating cadence for executive teams and boards Previously, I've held leadership roles at industry leaders such as Catalent, Morgan Stanley, Bridgewater Associates, and Illinois Tool Works, where I developed deep experience across pharmaceuticals, financial services, hedge funds, and global industrials. I began my career as an officer in the U.S. Navy, leading global teams responsible for operations in mission-critical environments. That experience shaped the leadership philosophy I bring to every organization: clarity of mission, disciplined execution, and building teams capable of delivering results under pressure. Today, my focus remains consistent: helping leadership teams align people strategy, operating models, and execution to create durable enterprise value. CHRO / Chief People Officer • Financial Services • Organizational Transformation • M&A Integration • Global HR Strategy • Operating Model Design • Change Management
Advisor to CEOs, Presidents and Boards of PE-backed and growth-stage companies on HR transformations, org design, enterprise scale-ups, operating model transitions, M&A integration, restructures, and leadership team effectiveness.
Led HR team as first ever CHRO for a mid-Atlantic regional law firm reporting into the CEO and Managing Partner. Responsible for firm’s HR vision, strategy and operations including talent acquisition, performance management, learning and capability development, compensation & benefits, DEI, organizational effectiveness, and evolving the firm's leadership and culture for 100+ attorneys and legal staff as the firm underwent a significant organizational redesign, scale up in legal headcount(+65%), comp & benefit realignment and multi-state expansion adding 3 new practice locations (PA/VA/DC).
Chief-of-Staff to the President & CFO of REEF, a multi-business, multi-site firm backed by Tier 1 investors (Softbank/Mubadala/Oaktree Capital) generating $1B+ in annual revenue with 18K employees globally. Created Office of the President while establishing enterprise governance practices, OKR/KPI dashboards and reporting processes, board-level presentations and investor relations materials, and steering committees for several large-scale transformation initiatives across the firm (i.e. M&A integrations, national hiring campaigns, ERP implementation, business process outsourcing/offshoring). Provided HRBP support to executive leadership of IT, Finance, Corporate Development and Legal departments while augmenting HR department following loss of incumbent CHRO which included creation of a new stand-alone Finance/Investment/Corporate Development recruiting function and operational turnaround of the company's field-based hourly and executive recruiting operations.
Led HR function reporting into the President of Paragon Bioservices, a PE-backed gene therapy CDMO, during a rapid scale-up of org from 30 to 2000 employees including HR team expansion from 3 to 14 personnel and ARR growth from $5M to $300M in 18 months; facility expansion from one university-based location to 5 international GMP-compliant manufacturing sites across US and Europe; M&A diligence and integration of 2 acquisitions (Novavax/MaSTherCell); and 1st ever FDA certification of a commercial gene therapy manufacturer during a global health crisis culminating in successful exit through public acquisition by Catalent Pharma Solutions (now Novo Nordisk) at $1.2B valuation. Led year-long integration of Paragon post-acquisition including rebranding as Catalent Gene Therapy and creation of new Catalent Biologics Division.